Genetron Health to Announce Fourth Quarter & Full Year 2020 Unaudited Financial Results & Host Investor Call on March 25, 2021
March 04 2021 - 5:00PM
Business Wire
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ:GTH), a leading precision oncology platform company in China
that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced that it will report unaudited financial results for
the fourth quarter and full year ended December 31, 2020 on March
25, 2021 before the US market open.
Management will host a conference call for investors at 8:30
a.m. ET (8:30 p.m. Beijing time) on Thursday, March 25, 2021. The
conference call can be accessed by dialing the following
numbers:
United States:
+1-845-675-0437
China Domestic:
400-620-8038
Hong Kong:
+852-3018-6771
International:
+65-6713-5090
Conference ID:
5379298
Participants are encouraged to dial into the call at least 15
minutes in advance due to high call volumes.
A replay will be accessible through April 2, 2021 by dialing the
following numbers:
Telco replay number
United States:
+1-855-452-5696
International:
+61-2-8199-0299
Conference ID:
5379298
A simultaneous webcast of the conference call will be available
on the "News and Events" page of the Investors section of the
Company's website. A replay of the webcast will be available for 30
days following the event. For more information, please visit
ir.genetronhealth.com.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq:GTH) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Statements that
are not historical facts, including statements about the Company’s
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties, and a number of factors could cause actual results
to differ materially from those contained in any forward-looking
statement. In some cases, forward-looking statements can be
identified by words or phrases such as “may”, “will,” “expect,”
“anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “potential,” “continue,” “is/are likely to” or other
similar expressions. Further information regarding these and other
risks, uncertainties or factors is included in the Company’s
filings with the SEC. All information provided in this press
release is as of the date of this press release, and the Company
does not undertake any duty to update such information, except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210304006053/en/
Investor Relations Contact US: Hoki
Luk Head of Investor Relations Email: hluk@genetronhealth.us Phone:
+1 (408) 891-9255
David Deuchler, CFA Managing Director | Gilmartin Group Email:
David@gilmartinir.com Phone: (917) 209-5605
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Apr 2023 to Apr 2024